MedPath

SYNRIBO

These highlights do not include all the information needed to use SYNRIBO safely and effectively. See full prescribing information for SYNRIBO. SYNRIBO (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012

Approved
Approval ID

83a504ef-cf92-467d-9ecf-d251194a3484

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 30, 2022

Manufacturers
FDA

Cephalon, LLC

DUNS: 183236314

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Omacetaxine Mepesuccinate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63459-177
Application NumberNDA203585
Product Classification
M
Marketing Category
C73594
G
Generic Name
Omacetaxine Mepesuccinate
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateNovember 28, 2023
FDA Product Classification

INGREDIENTS (2)

OMACETAXINE MEPESUCCINATEActive
Quantity: 3.5 mg in 1 mL
Code: 6FG8041S5B
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SYNRIBO - FDA Drug Approval Details